<DOC>
	<DOC>NCT00697476</DOC>
	<brief_summary>The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer</brief_summary>
	<brief_title>Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically or cytologically proven diagnosis of SCLC; Limited or extensivestage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of firstline chemotherapy (sensitive relapse); Age &gt;/= 18 years; ECOG Performance Status 02; Life expectancy of at least 12 weeks; Measurable lesions according to RECIST criteria; Adequate cardiac, hepatic, renal, and bone marrow function; Written informed consent. Prior treatment with an HDAC inhibitor; Symptomatic and/or unstable preexisting brain metastases; Superior Vena Cava Syndrome; Spinal cord compression; Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections); Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ; Pregnant or breastfeeding women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>second line chemotherapy</keyword>
</DOC>